Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 October 2022 | Story Anthony Mthembu | Photo Kaleidoscope
Tobias van den Bergh
Tobias van den Bergh, President of the Southern African Association for Counselling and Development in Higher Education (SAACHDE)

Tobias van den Bergh, Counselling Psychologist at the University of the Free State, has been appointed as the President of the Southern African Association for Counselling and Development in Higher Education (SAACDHE).  The appointment became official at the annual SAACDHE conference, which took place in Pretoria from 12 to 14 September 2022. As such, van den Bergh perceives this appointment as an opportunity: “To be part of a creative process that tackles the challenges faced in higher education and knowing the difficulty that students and my colleagues across the country are struggling with, accepting this appointment felt right.”

The role of SAACDHE

“The organisation represents members of several higher education counselling and career development centres from the SADC region. The organisation’s mission is to promote, guide, and advance best practices in centres at institutions of higher education,” explained Van den Bergh. Through this representation and assistance, members are able to provide quality support to the students they serve. SAACDHE members include mental health professionals, social workers, HIV/AIDS counsellors, researchers, and career development specialists from more than 15 higher education institutions in South Africa and Botswana. Furthermore, Van den Bergh asserts that, “SAACDHE represents its members through lobbying for increased institutional support, the promotion of scholarly, ethical, and best practices, and the training and development of professionals.”

Van den Bergh as President of the organisation

 As the newly elected President of the organisation, there are several challenges that Van den Bergh believes require the immediate attention of SAACDHE.  For instance, he maintains that student populations and the mental health challenges they face have grown at a substantial rate over the past few decades. However, the staff capacity in counselling and career development centres has not increased commensurately. As such, the challenge in this regard is that the need for mental health interventions continues to grow, but the capacity is not sufficient to deal with those challenges and to fill the gap in public mental health services. To address this challenge, he indicates that “the organisation is striving to innovate counselling centres, and to find ways to work smarter and be preventative where possible”.

In addition, Van den Bergh is adamant about ensuring that the organisation continues to be innovative in the way mental health services are provided to students, and to create practices that are culturally and contextually relevant. However, his long-term vision for the organisation is, “to continue serving as a training, development, and practice-based organisation, so that we can equip members with support and knowledge that will help them to continue helping students in a smarter and better way”.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept